Medical professionals reviewing screenings on two computer monitors

University of Maryland St. Joseph Medical Center's (UM SJMC) Cancer Institute is an active partner in advancing the understanding and treatment of cancer through clinical trials and research studies of people who have cancer. The goal of these studies is to find better ways to treat, diagnose and prevent cancer so that people can live better and longer.

Clinical trials are the engine of cancer research and can represent a patient's best chance for effective therapy. The clinical trials offered at UM St. Joseph Medical Center include preventive, treatment and observational research studies. They are based on nationally approved standards of cancer care and are designed to research how we can best improve our patients' cancer outcomes.

Patients have access to national, investigator-initiated and industry-sponsored clinical trials. The UM SJMC research team can help determine if a treatment option is right for a particular patient. As with all clinical trials, patients who enroll must meet specific criteria. Clinical trials currently in process at UM SJMC's Cancer Institute are below.

"There are many great reasons to be part of a clinical trial," says Kimberly Schlesinger, MD, medical director of the Cancer Institute at UM St. Joseph Medical Center. "If you think a clinical trial may be right for you, talk to your doctor to learn more."

Breast Cancer

  • S1418/BR006:
    A randomized phase III trial to evaluate the efficacy and safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with ≥ 1 cm residual invasive cancer or positive lymph nodes (ypN+) after neoadjuvant chemotherapy.
  • A011401:
    A randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer.
  • A011202:
    A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (CTI-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy.
  • A011502:
    The ABC Trial: A randomized phase III double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for HER2 negative breast cancer.
  • S1207:
    E3 Breast Cancer Study-evaluating everolimus with endocrine therapy: a phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/neu-negative breast cancer.
  • Polaris:
    Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study.

Pancreatic Cancer

  • ARMO:
    A randomized phase III study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second-line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first-line gemcitabine containing regimen.

Non-Hodgkin's Lymphoma

  • UTX-TGR-205: image of someone holding a vile that is labeled platelet count
    A Phase 2b randomized study to assess the efficacy and safety of the combination of ublituximab + TGR-1202 with or without bendamustine and TGR-1202 alone in patients with previously treated Non-Hodgkin's lymphoma.

All Cancers

  • Maryland Cancer Survivorship Cohort

Radiation Oncology

  • NRG CC003:
    Testing whether avoiding the hippocampus during whole-brain radiation therapy prevents cognitive side effects in patients with small cell lung cancer


    Prospective registry of multiplex testing, a research registry for people who have had a newer form of genetic testing, called multi-gene panels.

For more information about clinical trials at UM SJMC, please call 410-337-4569.